Trial Profile

A phase II study of naloxone nasal spray for the treatment of opioid overdose reversal

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jun 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naloxone (Primary)
Indications Opioid-related disorders
Focus Registrational; Therapeutic Use

Most Recent Events

09 Jun 2016 According to a Lightlake therapeutics media release, the company plans to report top-line results of this trial in H1 2017.
06 May 2016 According to a Adapt Pharma Limited media release, the company has done a new drug submission (NDS) of naloxone nasal spray to Health Canada for the emergency reversal of opioid overdose.
19 Nov 2015 According to a Adapt Pharma Limited media release, the U.S. Food and Drug Administration (FDA) has approved NARCAN (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com